Subsequently, we analyzed the association of MCM7 expression with clinical outcomes, and found that expression of MCM7 in NSCLC patients was significantly associated with male gender (P < 0.0001, Fisher's exact test; Table 1), non-adenocarcinoma (ADC) histology (P < 0.0001), presence of lymph node metastasis (pN1-2; P < 0.0001) and tumor-specific 5-year survival after the resection of primary tumors (P = 0.0055 by log-rank test; Figure 1D). This evidence concerns the gene MCM7 and metastatic malignant neoplasm in the lymph nodes.